Acute Liver Failure SIG

Steering Committee Members

  • Audrey Coilly, Hopital Paul Brousse, Villejuif, France – Topic Coordinator
  • Isabel Conde Amiel, Hospital Universitario La Fe, Valencia, Spain – Topic Coordinator
  • Nazia Selzner, University of Toronto, Toronto, Canada – Topic Coordinator
  • Florent Artru, University Hospital of Lausanne, Switzerland
  • Ahmet Gurakar, Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Constantine Karvellas, University Of Alberta Hospital, Edmonton, Canada
  • Akila Rajakumar, Dr Rela Institute & Medical Centre, Chennai, India
  • Fuat Saner, Klinik für Allgemeine und Transplantationschirurgie Universitätsklinikum Essen, Germany
  • Ram Subramanian, Emory University Hospital, Decatur, GA, USA
  • Li-Ying Sun, Beijing Friendship Hospital, Beijing, China

 

This new SIG will become active soon. The following is an outline proposal submitted by Audrey Coilly, SIG Topic Co-ordinator, February 2021

The Acute Liver Failure Special Interest Group has been created to promote communication, education and research among clinicians managing patients with acute liver failure, especially with reference to selection for and management of transplantation.

ALF is a rare condition characterised by severe hepatocyte injury evolving over days or weeks and often progressing to lethal multi-organ failure. Despite significant recent advances, liver transplantation is the only life-saving treatment in around 30% of cases. Causes of ALF are numerous, including paracetamol toxicity, other drug and toxin-induced liver injury, viral hepatitis (A, B or E) , autoimmune hepatitis, Wilson’s disease, hepatic ischemia, Budd-Chiari Syndrome, pregnancy-associated conditions and malignant infiltration. In 20 – 50% of cases, a cause cannot be determined. Diagnostic strategies vary widely around the world, but always require careful review of medication and dietary exposure, serological testing for viral and autoimmune causes, and liver imaging.

Because of its rarity, acute liver failure has not been studied in large, randomized trials. Most treatment recommendations are based on observational studies and expert opinion.

SIG Aims

 

  • To promote communication between clinicians treating patients with ALF, allowing them to share experiences and information on clinical practice,
  • To encourage international and multidisciplinary involvement in ALF research and education
  • To disseminate ALF research findings through enhanced ILTS educational initiatives, including the Annual Congress, dedicated webinars, single-topic meetings, and joint meetings such as the AASLD-ILTS Transplant Course
  • To develop research questions, consensus statements and clinical guidelines on liver transplantation for ALF,
  • To collaborate with other organisations to promote research and standards of care in this condition.

Proposed topics of interest for 2021-22, to be determined by Steering Committee

 

Variation in causes of ALF worldwide

  • Explore development of an international registry through ILTS membership networks. Data fields to be defined and analysed by the SIG Steering Committee
  • Develop an international survey to identify variations in diagnostic approach

These initiatives could inform regionally-standardised etiological investigation and quality assurance strategies.

 

Therapeutic management

  • Use the dedicated SIG email platform to share opinions on challenging cases
  • Develop surveys to better understand ALF indications, management and access to liver transplantation around the world, in particular the role of liver dialysis devices

Potential future investigations

  • Immediate causes of mortality in ALF, particularly bacterial sepsis and cerebral oedema
  • Rare causes of ALF, elucidated through registry analysis

 

 

Edited by J R Klinck, ILTS Special Projects, 9 February 2021